Alard E, Butnariu A, Grillo M, Kirkham C, Zinovkin D, Newnham L
Cancers (Basel). 2020; 12(7).
PMID: 32645977
PMC: 7408985.
DOI: 10.3390/cancers12071826.
Jung I, Lee J
Mol Cells. 2018; 41(8):717-723.
PMID: 30110720
PMC: 6125425.
DOI: 10.14348/molcells.2018.0242.
Veenstra C, Krauss J
Clin Colon Rectal Surg. 2018; 31(3):179-191.
PMID: 29720904
PMC: 5929883.
DOI: 10.1055/s-0037-1602238.
Serganova I, Moroz E, Cohen I, Moroz M, Mane M, Zurita J
Mol Ther Oncolytics. 2017; 4:41-54.
PMID: 28345023
PMC: 5363727.
DOI: 10.1016/j.omto.2016.11.005.
Katz S, Burga R, McCormack E, Wang L, Mooring W, Point G
Clin Cancer Res. 2015; 21(14):3149-59.
PMID: 25850950
PMC: 4506253.
DOI: 10.1158/1078-0432.CCR-14-1421.
Clinical application of genetically modified T cells in cancer therapy.
Kershaw M, Westwood J, Slaney C, Darcy P
Clin Transl Immunology. 2014; 3(5):e16.
PMID: 25505964
PMC: 4232070.
DOI: 10.1038/cti.2014.7.
Recombination-deletion between homologous cassettes in retrovirus is suppressed via a strategy of degenerate codon substitution.
Im E, Bais A, Yang W, Ma Q, Guo X, Sepe S
Mol Ther Methods Clin Dev. 2014; 1:14022.
PMID: 25419532
PMC: 4239131.
DOI: 10.1038/mtm.2014.22.
Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.
Sengupta S, Thaci B, Crawford A, Sampath P
Biomed Res Int. 2014; 2014:952128.
PMID: 25247196
PMC: 4163479.
DOI: 10.1155/2014/952128.
Cell transfer therapy for cancer: past, present, and future.
Qian X, Wang X, Jin H
J Immunol Res. 2014; 2014:525913.
PMID: 24741604
PMC: 3987872.
DOI: 10.1155/2014/525913.
Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells.
Sahu G, Sango K, Selliah N, Ma Q, Skowron G, Junghans R
Virology. 2013; 446(1-2):268-75.
PMID: 24074590
PMC: 3791854.
DOI: 10.1016/j.virol.2013.08.002.
Gene-engineered T cells for cancer therapy.
Kershaw M, Westwood J, Darcy P
Nat Rev Cancer. 2013; 13(8):525-41.
PMID: 23880905
DOI: 10.1038/nrc3565.
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.
Maher J
ISRN Oncol. 2013; 2012:278093.
PMID: 23304553
PMC: 3523553.
DOI: 10.5402/2012/278093.
Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
Kong S, Sengupta S, Tyler B, Bais A, Ma Q, Doucette S
Clin Cancer Res. 2012; 18(21):5949-60.
PMID: 22966020
PMC: 4337849.
DOI: 10.1158/1078-0432.CCR-12-0319.
Cell density plays a critical role in ex vivo expansion of T cells for adoptive immunotherapy.
Ma Q, Wang Y, Lo A, Gomes E, Junghans R
J Biomed Biotechnol. 2010; 2010:386545.
PMID: 20625484
PMC: 2896674.
DOI: 10.1155/2010/386545.
Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies.
Junghans R
J Transl Med. 2010; 8:55.
PMID: 20537174
PMC: 2904270.
DOI: 10.1186/1479-5876-8-55.
Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation.
Emtage P, Lo A, Gomes E, Liu D, Gonzalo-Daganzo R, Junghans R
Clin Cancer Res. 2008; 14(24):8112-22.
PMID: 19088026
PMC: 2659496.
DOI: 10.1158/1078-0432.CCR-07-4910.
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
Pinthus J, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I
J Clin Invest. 2004; 114(12):1774-81.
PMID: 15599402
PMC: 535069.
DOI: 10.1172/JCI22284.
